Lilly Humalog European Labeling Adds HbA1c Lowering Claim
Executive Summary
Revised EU labeling for Lilly's Humalog (insulin lispro) includes a claim that the insulin analog reduces hemoglobin A1c more effectively than soluble insulin when administered in subcutaneous infusion pumps.
You may also be interested in...
Aventis Apidra Clears FDA; Launch Of Fast-Acting Insulin Awaits Delivery Pen
Aventis will wait to launch the rapid-acting recombinant human insulin analog Apidra until after approval of the OptiClick pen delivery device
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011